Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Nizzoli

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
American Journal of Hematology|June 4, 2020
Circulating endothelial cells in COVID-19Maria E Nizzoli, Gabriele Merati, Annamaria Tenore, et al.
British Journal of Haematology|July 6, 2019
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disordersMarzia Varettoni, Silvia Zibellini, Emanuela Boveri, et al.
Hemasphere|December 19, 2024
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) studyAlberto Bavieri, Maria E Nizzoli, Alessandra Tucci, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
American Journal of Hematology|June 4, 2020
Circulating endothelial cells in COVID-19Maria E Nizzoli, Gabriele Merati, Annamaria Tenore, et al.
British Journal of Haematology|July 6, 2019
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disordersMarzia Varettoni, Silvia Zibellini, Emanuela Boveri, et al.
Hemasphere|December 19, 2024
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) studyAlberto Bavieri, Maria E Nizzoli, Alessandra Tucci, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
Pageof 1